The evolution of durvalumab in NSCLC care
Hospital Pharmacy Europe
NOVEMBER 4, 2024
That’s been driven by advancements in targeted therapies, immunotherapy and the more personalised approach to patient care,’ he says. This could include educational initiatives such as workshops, seminars and webinars focused on the role of durvalumab in non-small cell lung cancers. I’m optimistic we’ll see that.’
Let's personalize your content